drugset / Trial / NCT01873508

A Study of Three Modified-Release Formulations of RO4917523 in Healthy Volunteers

NCT01873508

Phase 1 Completed 24 enrolled Hoffmann-La Roche
RandomizedCrossoverOpen-label

Summary

This single-center, open label, randomized, 3-period cross-over study will compare 3 modified-release formulations of RO4917523 in healthy volunteers. Subjects will be randomized to one of six sequences to receive single oral doses of RO4917523 slow, target and fast release modified release (MR) capsules along with a reference intravenous microdose with the target capsule. A washout period of at least 21 days will occur between treatments.

Timeline

Start
2013-06
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Basimglurant Small molecule Oral

Indications

No indication recorded.